tradingkey.logo

Nanovibronix Inc

NAOV
4.020USD
0.000
收盤 12/24, 13:00美東報價延遲15分鐘
4.06M總市值
虧損本益比TTM

Nanovibronix Inc

4.020
0.000

關於 Nanovibronix Inc 公司

NanoVibronix, Inc. is a medical device company focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The Company's primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use.

Nanovibronix Inc簡介

公司代碼NAOV
公司名稱Nanovibronix Inc
上市日期Apr 24, 2015
CEOBesser (Doron)
員工數量15
證券類型Ordinary Share
年結日Apr 24
公司地址969 Pruitt Piace
城市TYLER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編75703
電話19142333004
網址https://nanovibronix.com/
公司代碼NAOV
上市日期Apr 24, 2015
CEOBesser (Doron)

Nanovibronix Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
United States
462.00K
93.52%
New Zealand
20.00K
4.05%
Europe
8.00K
1.62%
Other
4.00K
0.81%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月3日 週三
更新時間: 12月3日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Alpha Capital Aktiengesellschaft
0.76%
Geode Capital Management, L.L.C.
0.47%
Armistice Capital LLC
0.37%
Morgan Stanley Smith Barney LLC
0.09%
Tower Research Capital LLC
0.06%
其他
98.25%
持股股東
持股股東
佔比
Alpha Capital Aktiengesellschaft
0.76%
Geode Capital Management, L.L.C.
0.47%
Armistice Capital LLC
0.37%
Morgan Stanley Smith Barney LLC
0.09%
Tower Research Capital LLC
0.06%
其他
98.25%
股東類型
持股股東
佔比
Holding Company
0.76%
Investment Advisor/Hedge Fund
0.47%
Hedge Fund
0.42%
Investment Advisor
0.11%
其他
98.23%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
17
5.95K
0.68%
+2.34K
2025Q2
26
142.96K
5.53%
+80.02K
2025Q1
26
100.49K
7.64%
+70.73K
2024Q4
29
390.46K
7.75%
-206.57K
2024Q3
31
421.26K
15.22%
+83.76K
2024Q2
31
243.60K
8.84%
-214.51K
2024Q1
34
373.91K
18.23%
+170.33K
2023Q4
38
117.62K
5.71%
-262.96K
2023Q3
41
131.29K
7.90%
-1.54K
2023Q2
41
49.26K
2.96%
-111.70K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Alpha Capital Aktiengesellschaft
8.25K
0.95%
+4.93K
+148.55%
May 16, 2025
Geode Capital Management, L.L.C.
--
0%
-205.00
-100.00%
Mar 31, 2025
Armistice Capital LLC
3.99K
0.46%
+3.99K
--
Mar 31, 2025
Tower Research Capital LLC
226.00
0.03%
+124.00
+121.57%
Jun 30, 2025
The Vanguard Group, Inc.
--
0%
-274.00
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
1.37K
0.16%
+854.00
+165.50%
Jun 30, 2025
Fashek (Christopher M)
34.00
0%
--
--
May 16, 2025
SBI Securities Co., Ltd.
--
0%
--
--
Jun 30, 2025
BofA Global Research (US)
1.00
0%
--
--
Jun 30, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Aug 08, 2025
Merger
10→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
公告日期
類型
比率
Aug 08, 2025
Merger
10→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1

常見問題

Nanovibronix Inc的前五大股東是誰?

Nanovibronix Inc的前五大股東如下:
Alpha Capital Aktiengesellschaft
持有股份:8.25K
佔總股份比例:0.95%。
Geode Capital Management, L.L.C.
持有股份:0.00
佔總股份比例:0.00%。
Armistice Capital LLC
持有股份:3.99K
佔總股份比例:0.46%。
Tower Research Capital LLC
持有股份:226.00
佔總股份比例:0.03%。
The Vanguard Group, Inc.
持有股份:0.00
佔總股份比例:0.00%。

Nanovibronix Inc的前三大股東類型是什麼?

Nanovibronix Inc 的前三大股東類型分別是:
Alpha Capital Aktiengesellschaft
Geode Capital Management, L.L.C.
Armistice Capital LLC

有多少機構持有Nanovibronix Inc(NAOV)的股份?

截至2025Q3,共有17家機構持有Nanovibronix Inc的股份,合計持有的股份價值約為5.95K,占公司總股份的0.68% 。與2025Q2相比,機構持股有所增加,增幅為-4.85%。

哪個業務部門對Nanovibronix Inc的收入貢獻最大?

在FY2025Q2,--業務部門對Nanovibronix Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI